Literature DB >> 7901234

Vasoactive intestinal peptide inhibits interleukin (IL)-2 and IL-4 production through different molecular mechanisms in T cells activated via the T cell receptor/CD3 complex.

L Sun1, D Ganea.   

Abstract

The neuropeptide vasoactive intestinal peptide (VIP) has been reported previously to inhibit cell proliferation and interleukin (IL)-2 production in mitogen-stimulated T lymphocytes. In physiological conditions, T lymphocytes are specifically activated by antigen-binding through the T cell receptor (TCR). Here we report on the effect of VIP and related peptides on IL-2 and IL-4 production of murine T lymphocytes stimulated through the TCR. VIP inhibited IL-2 and IL-4 production (both at the level of protein concentration and biological activity) by unfractionated spleen cells or purified CD4+ T cells stimulated with either anti-CD3 monoclonal antibodies (mAbs) or with anti-CD3 mAbs plus phorbol esters. The inhibition was dose-dependent, and specific, since structurally related peptides such as secretin and glucagon had little or no inhibitory activity. VIP inhibited IL-2 and IL-4 production through different molecular mechanisms. IL-2 production was regulated at a transcriptional level through the downregulation of IL-2 mRNA, whereas the production of IL-4 was modulated at a posttranscriptional level.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7901234     DOI: 10.1016/0165-5728(93)90059-8

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  6 in total

1.  Characterization and use of a rabbit-anti-mouse VPAC1 antibody by flow cytometry.

Authors:  Rebecca J Hermann; Travis Van der Steen; Emilie E Vomhof-Dekrey; Sejaa Al-Badrani; Steve B Wanjara; Jarrett J Failing; Jodie S Haring; Glenn P Dorsam
Journal:  J Immunol Methods       Date:  2011-11-04       Impact factor: 2.303

2.  Predominant expression of type II vasoactive intestinal peptide receptors by human T lymphoblastoma cells: transduction of both Ca2+ and cyclic AMP signals.

Authors:  M Xia; S P Sreedharan; E J Goetzl
Journal:  J Clin Immunol       Date:  1996-01       Impact factor: 8.317

3.  Enhanced delayed-type hypersensitivity and diminished immediate-type hypersensitivity in mice lacking the inducible VPAC(2) receptor for vasoactive intestinal peptide.

Authors:  E J Goetzl; J K Voice; S Shen; G Dorsam; Y Kong; K M West; C F Morrison; A J Harmar
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-06       Impact factor: 11.205

4.  Identification of cyclic AMP phosphodiesterases 3, 4 and 7 in human CD4+ and CD8+ T-lymphocytes: role in regulating proliferation and the biosynthesis of interleukin-2.

Authors:  M A Giembycz; C J Corrigan; J Seybold; R Newton; P J Barnes
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

5.  Levels of gastrin-releasing peptide and substance P in synovial fluid and serum correlate with levels of cytokines in rheumatoid arthritis.

Authors:  Ola Grimsholm; Solbritt Rantapää-Dahlqvist; Sture Forsgren
Journal:  Arthritis Res Ther       Date:  2005-02-07       Impact factor: 5.156

Review 6.  Human T Lymphotropic Virus Type I (HTLV-I) Oncogenesis: Molecular Aspects of Virus and Host Interactions in Pathogenesis of Adult T cell Leukemia/Lymphoma (ATL).

Authors:  Sanaz Ahmadi Ghezeldasht; Abbas Shirdel; Mohammad Ali Assarehzadegan; Tahereh Hassannia; Hosian Rahimi; Rahele Miri; S A Rahim Rezaee
Journal:  Iran J Basic Med Sci       Date:  2013-03       Impact factor: 2.699

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.